Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer
- PMID: 21172881
- DOI: 10.1200/JCO.2010.31.6679
Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer
Erratum in
-
Errata.J Clin Oncol. 2019 Feb 1;37(4):353. doi: 10.1200/JCO.18.02189. J Clin Oncol. 2019. PMID: 30695657 No abstract available.
Comment on
-
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.J Clin Oncol. 2011 Feb 1;29(4):398-405. doi: 10.1200/JCO.2010.29.5865. Epub 2010 Dec 20. J Clin Oncol. 2011. PMID: 21172893 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
